Distillate Capital Partners’s Boston Scientific BSX Stock Holding History

Distillate Capital Partners’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.2M	Buy	+450,915	New	+$24.5M	1%	36

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Distillate Capital Partners's BSX Position: Q2 2026 in Review

Distillate Capital Partners opened a new position in Boston Scientific (BSX) in Q2 2026: 450,915 shares worth $19.2M. The stake represents 1% of the portfolio and ranks #36 among its holdings.

1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Distillate Capital Partners held 450,915 shares of Boston Scientific worth $19.2M as of Q2 2026.
Boston Scientific was a new Distillate Capital Partners position in Q2 2026.
Boston Scientific made up 1% of Distillate Capital Partners's portfolio in Q2 2026, its #36 holding.
1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Distillate Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.